Form 4: GoodRx Holdings Executive Romin Nabiey Reports Stock Transactions
SEC Form 4 Filing
Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.
Summary
- On May 8, 2025, Romin Nabiey, the Chief Accounting Officer of GoodRx Holdings, Inc., reported transactions involving Class A Common Stock.
- 12,663 shares of Class A Common Stock were acquired through the vesting of restricted stock units.
- 4,531 shares were disposed of to satisfy tax withholding obligations at a price of $3.79 per share.
- Following these transactions, Nabiey directly owns 115,006 shares of Class A Common Stock and 101,302 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by an executive. It doesn't indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/08/2023 | 6.25% of the restricted stock units vest |
| 05/08/2025 | Date of transaction: vesting of restricted stock units and disposal of shares for tax obligations |
Keywords
GoodRx Holdings, GDRX, Romin Nabiey, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.